← Eichor
Study identifier: NCT06862089 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

A Prospective Study Evaluating the Impact of Conservative Management on Retained Products of Conception and EMV

Condition: Retained Products of Conception · Miscarriage · Conservative Management  ·  Sponsor: Fu Xing Hospital, Capital Medical University

PhaseN/A
Planned participants120
Who can joinFemale, N/A to no upper limit
Healthy volunteersNo

About this study

The goal of this observational study is to learn about the therapeutic effects of the conservative treatment approach on pepole with retained products of conception (RPOC) and Enhanced myometrial vascularity (EMV). The main question it aims to answer is: Is it possible to achieve the natural resolution of RPOC by combining it with EMV through conservative treatment? Participants will receive conservative treatment (such as mifepristone, GnRH-a, or expectant management) following the initial diagnosis of RPOC and EMV, and the therapeutic efficacy of the conservative approach will be assessed after the completion of two menstrual cycles.

This description comes directly from the study's public registry record.

Talk to the study team

Rui Huang  ·  +86 18610317613  ·  blueberry0801@foxmail.com

Always discuss trial participation with your own doctor first.

Locations (1)

Hysteroscopy Center, Fuxing Hospital, Capital Medical UniversityBeijing, ChinaRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06862089